CAS No. |
103060-53-3 |
中文名称 |
2,2'-((3S,6S,9R,15S,18R,21S,24S,30S,31R)-30-((S)-2-((R)-4-氨基-2-((S)-2-癸酰胺基-3-(1H-吲哚-3-基)丙酰胺基)-4-氧代丁酰胺基)-3-羧基丙酰胺基)-3-(2-(2-氨基苯基)-2-氧代乙基)-24-(3-氨基丙基)-6-((R)-1-羧基丙烷-2-基)-9-(羟甲基)-18,31-二甲基-2,5,8,11,14,17,20,23,26,29-十氧代-1-氧杂-4,7,10,13,16,19,22,25,28-九氮杂环三十一烷-15,21-二基)二乙酸 |
英文名称 |
2,2'-((3S,6S,9R,15S,18R,21S,24S,30S,31R)-30-((S)-2-((R)-4-amino-2-((S)-2-decanamido-3-(1H-indol-3-yl)propanamido)-4-oxobutanamido)-3-carboxypropanamido)-3-(2-(2-aminophenyl)-2-oxoethyl)-24-(3-aminopropyl)-6-((R)-1-carboxypropan-2-yl)-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontane-15,21-diyl)diacetic acid |
别名 |
SR-01000872587 | SCHEMBL28102 | N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,1 |
标准英文名 |
2,2'-((3S,6S,9R,15S,18R,21S,24S,30S,31R)-30-((S)-2-((R)-4-amino-2-((S)-2-decanamido-3-(1H-indol-3-yl)propanamido)-4-oxobutanamido)-3-carboxypropanamido)-3-(2-(2-aminophenyl)-2-oxoethyl)-24-(3-aminopropyl)-6-((R)-1-carboxypropan-2-yl)-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontane-15,21-diyl)diacetic acid |
MDL No. |
MFCD08282794 |
分子式 |
C72H101N17O26 |
分子量 |
1620.69
|
精确分子量 |
1619.71
|
SMILES |
CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)C2=CC=CC=C2N)C(=O)O[C@@H]1C |
标准SMILES |
CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=CC=CC=C2N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O |
用途 |
Treatment of complicated skin and skin structure infections caused by susceptible Gram-positive bacteria; treatment of serious Gram-positive bacterial infections including endocarditis, bacteremia, sepsis, peritonitis, and urinary tract infections, particularly those caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and linezolid-resistant isolates; treatment of right-sided infective endocarditis caused by Staphylococcus aureus and associated Staphylococcus aureus bacteremia; pharmaceutical intermediate. |
InChIKey |
DOAKLVKFURWEDJ-QCMAZARJSA-N |